SFM
CDTX

Sphera Funds Management’s Cidara Therapeutics CDTX Stock Holding History

Sphera Funds Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$9.58M – 104
2025
Q3 		$9.58M Buy
+100,000
New +$6.38M 2.02% 11

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Sphera Funds Management's CDTX Position: Q4 2025 in Review

Sphera Funds Management sold out of Cidara Therapeutics (CDTX) in Q4 2025, closing a stake of 75,743 shares — an estimated $7.25M sold.

Sphera Funds Management first reported a position in CDTX in Q4 2017 and held it in 4 quarters. The position peaked at $7.25M in Q3 2025. 255 funds tracked by Wall St. Rank hold CDTX as of Q4 2025.

  • Sphera Funds Management reported no remaining Cidara Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sphera Funds Management sold 75,743 Cidara Therapeutics shares in Q4 2025, an estimated $7.25M.
  • Sphera Funds Management first reported a position in Cidara Therapeutics in Q4 2017 and held it in 4 quarters.
  • Sphera Funds Management's Cidara Therapeutics position peaked at $7.25M in Q3 2025.
  • 255 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2025.

Based on Sphera Funds Management's 13F filing for Q4 2025, filed 17 Feb 2026.